Abstract
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Highlights
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
We have identified efficient presentation of antigen in the context of MHC class I and MHC class II as well as homing capabilities to secondary lymphoid organs as essential biological criteria for this cellular adjuvant to merit further development
We showed that antigenloaded CD40-B cells expand memory and induce primary CD8+ T cell responses in healthy donors and cancer patients alike
Summary
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines. Published: 1 July 2004 Cancer Cell International 2004, 4(Suppl 1):S49 This article is available from: http://www.cancerci.com/content/4/S1/S49
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
